

Dinner Meeting

Thursday, November 15th, 2018

Topic: Vaginal Health and Dyspareunia

Speaker:

Deborah Wickman, MD, MS, FACOG, NCMP, CSC

Dr. Debra Wickman from Banner University presented drug information for Intrarosa (Prasterone).

Intrarosa is the first FDA approved vaginal non-estrogen therapy for dyspareunia.

Common complaint of dyspareunia in postmenopausal women attributed to vulvovaginal atrophy, estrogen products alone only treat the atrophy but not the vestibulitis of skene and bartholin Ostia which can also be contributory to dyspareunia.

Interosa is a suppository placed vaginally nightly, benefit typically appreciated by patient after 4-6 weeks of use.

Prasterone/DHEA is metabolized by the vaginal mucosa into androgens and estrogens, the hormonal effect was found in clinical studies to increase superficial cells of vaginal mucosa, decreased percentage of parabasal cells, but most importantly a statistically significant decrease in dyspareunia.

Only contraindication is undiagnosed abnormal vaginal bleeding, there was no significant estrogen levels appreciated in patient serum thus not contraindicated in patients where estrogen products would otherwise be contraindicated or avoided. Most common side effect is vaginal discharge, otherwise no limit on duration of use.

Through the Intrarosa official website (<https://us.intrarosa.com/>) additional information can be found in addition to copay card with possible \$0 copay the first month with no more than \$25 copay for additional 11months of first use.